News – Page 787 – Endpoints News

SIGN UP

Now a two-time loser, AstraZeneca’s hopes for selumetinib dwindle after another PhIII flop

7 years ago

Racing past a wounded Juno, Kite aims to file lead CAR-T for OK by end of 2016

7 years ago

Protocols: Allergan disses giant leaps, concentrates on stepping stones; AstraZeneca also gets a boost from ...

7 years ago

Acetylon can say goodbye to buyout and a $1B-plus in Celgene biobucks

7 years ago

Novartis's asthma ‘wonder drug’ basks in the bright spotlight of a UK media frenzy

7 years ago

Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study

7 years ago

Celgene stays focused on protein homeostasis, backs Cleave’s $37M round to fuel early studies

7 years ago

Allergan, Richter steer past another late-stage pileup with cariprazine

7 years ago

Protocols: Did Ionis set out to exclude side effects? Merck takes another step forward with Lantus biosimilar

7 years ago

Woodford gets slammed with a brutal set of portfolio hits, as Northwest continues to fester

7 years ago

Thumbs Up/Thumbs Down: The new buzz in R&D, blockbuster work on a budget and why what’s dead may never die

7 years ago

Bristol-Myers craters after blockbuster checkpoint drug Opdivo fails key lung cancer study

7 years ago

Gemphire IPO staggers into the market, reaping $30M

7 years ago

Deaths derail Juno's launch countdown, giving Kite and Novartis the lead

7 years ago

Pushed by high costs in Cambridge, fast-growing Decibel makes a pioneering leap to Fenway

7 years ago

Momenta hit with a setback as pancreatic cancer drug flops in PhII

7 years ago

Regeneron makes a blockbuster case for its PhIII drug pipeline

7 years ago

BioRegnum: What’s the deal with Biogen?

7 years ago

Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now

7 years ago

Protocols: Editas adds CRISPR/Cas9 IP; biosimilars make fresh gains in U.S. market

7 years ago

Takeda rests its R&D footprint on U.S. hubs

7 years ago

As doubts continue to fester, Inovio gets another shove as Roche exits collaboration

7 years ago

Novartis’ star cancer drug lands on an inside FDA track, racing Lilly to a showdown with Pfizer

7 years ago

Baxalta in hand, Shire dumps drug programs in hunt for $210M in R&D cuts

7 years ago

First page Previous page 784 785 786787788 789 790 Next page Last page